Efficacy and Safety Analysis of Insulin Degludec/Insulin Aspart (IDegAsp) Compared with Biphasic Insulin
Aspart 30 : A Phase 3, Multicenter, International, Open-label, Randomized, Treat-to-target Trial in Patients with Type 2 Diabetes Fasting during Ramadan.
Exposure to the twice-daily biphasic insulin
regimen, adjusted for other variables including total insulin exposure, was associated with a 0.
Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin
aspart as assessed by compartmental modeling, Diabetologia, 49(9): 2030-2038,
Patients previously treated with basal insulin experienced relatively greater A1C reductions with basal-bolus insulin than with biphasic insulin
The mean recovery of compounds was consistent, being 101 per cent for regular insulin and 82 per cent for regular insulin in biphasic insulin
Long-term cost effectiveness of biphasic insulin
aspart 30/70 versus insulin glargine in insulin naive patients with type 2 diabetes poorly controlled on oral hypoglycemin agents in Danish, Dutch, Finnish, French, German, Norwegian, Spanish, Swedish and UK settings.
A dual-action insulin co-formulation such as insulin I Deg Asp) scores over biphasic insulin
analogues and human insulins in achieving fasting euglycaemia, without causing nocturnal hypoglycaemia.
Using continious glucose monitoring to measure the frequency of low glucose values when using biphasic insulin
aspart 30 compared with biphasic human insulin 30.
Patients were randomized to biphasic insulin
aspart twice daily, prandial insulin aspart 3 limes daily, or basal insulin detemir once or twice daily.
The insulin users were further subdivided into users of glargine, long-acting human insulin, biphasic analogue, or human biphasic insulin
The researchers focussed on the safety and effectiveness of using the biphasic insulin
, which contains both fast-acting and intermediate components, prescribed by family doctors and hospital consultants.